Activity of high dose daptomycin, vancomycin and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm.

06:00 EDT 11th August 2010 | BioPortfolio

Summary of "Activity of high dose daptomycin, vancomycin and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm."

Biofilm is an important virulence factor that allows bacteria to resist host responses and antibacterial agents. The aim of the study was to assess the in-vitro activity of several antimicrobials alone or in combination against two Staphylococcus aureus isolates using a novel pharmacokinetic/pharmacodynamic model of biofilm for three days. One methicillin-susceptible S. aureus (SH1000) and one methicillin-resistant S. aureus (N315) were evaluated in a modified biofilm reactor with polystyrene coupons. Simulated regimens included vancomycin (VAN) plus RIF, moxifloxacin (MOX) and high dose (10 mg/kg/day) daptomycin (DAP) alone and combined with rifampin (RIF) or clarithromycin (CLA). Against SH1000 viable planktonic (PB) and biofilm-embedded bacteria (BB), neither DAP nor MOX alone were bactericidal. In contrast, combination of DAP and MOX with CLA significantly increased the activity of the two agents against both PB and BB (p<0.01), and DAP+CLA reached the limit of detection at 72h. Against PB of N315, DAP alone briefly achieved bactericidal activity at 24h, whereas sustained cidal activity was observed at 32h with VAN+RIF. Overall, only minimal reduction was observed with both regimens against BB (< 2.8 log10 CFU/mL). Finally, combination of DAP+RIF was bactericidal against both PB and BB, achieving the limit of detection at 72h. In conclusion, we developed a novel in-vitro PK/PD model to assess the activity of antimicrobials against mature bacterial biofilm. Combinations of DAP or MOX with CLA were the most effective regimens and may represent promising options to treat persistent infections caused by S. aureus biofilms.


Wayne State University, Anti-Infective Research Laboratory, Detroit, MI USA; Infectious Diseases Unit, HU San Cecilio, Granada-Spain; University of Wisconsin, Madison, WI. USA.

Journal Details

This article was published in the following journal.

Name: Antimicrobial agents and chemotherapy
ISSN: 1098-6596


DeepDyve research library

PubMed Articles [30389 Associated PubMed Articles listed on BioPortfolio]

Comparative Effectiveness and Safety of Standard-, Medium-, and High-Dose Daptomycin Strategies for the Treatment of Vancomycin-Resistant Enterococcal Bacteremia Among Veterans Affairs Patients.

Vancomycin-resistant Enterococcus bloodstream infections (VRE-BSI) are associated with significant mortality. Daptomycin exhibits concentration-dependent activity versus VRE in vitro, yet the clinical...

Effect of Daptomycin Dose on the Outcome of Vancomycin-Resistant, Daptomycin-Susceptible Enterococcus faecium Bacteremia.

Treatment options for vancomycin-resistant enterococci (VRE) bloodstream infection (BSI) are limited. Daptomycin, although not currently approved for this indication, is frequently used for the treatm...

Are moxifloxacin and levofloxacin equally effective to treat XDR tuberculosis?

: Moxifloxacin retains partial activity against some fluoroquinolone-resistant mutants of Mycobacterium tuberculosis . Levofloxacin is presumed to be as active as moxifloxacin against drug-susceptible...

Molecular State of the Membrane-Active Antibiotic Daptomycin.

Membrane-active antibiotics are potential alternatives to the resistance-prone conventional antibiotics. Daptomycin, a cyclic lipopeptide, is the only membrane-active antibiotic approved by the U.S. F...

Population pharmacokinetics and dosing considerations for the use of daptomycin in adult patients with haematological malignancies.

To assess the population pharmacokinetics (popPK) of daptomycin at the conventional dose of 6 mg/kg/day in a cohort of oncohaematological patients.

Clinical Trials [11307 Associated Clinical Trials listed on BioPortfolio]

A Study to Evaluate Daptomycin Given During Dialysis and After Dialysis

The purpose of this study is to determine whether daptomycin at a higher dose given during the last 30 minutes of a dialysis session is equal to a lower dose of daptomycin given after a di...

Daptomycin for the Treatment of Severe Necrotizing Soft-Tissue Infections

Daptomycin is a new antimicrobial agent which has activity against resistant Gram positive cocci including MRSA. The phase 3 clinical trials for skin and soft tissue infections (SSTI) with...

The Pharmacokinetics/Pharmacodynamics of High-dose Daptomycin in Patients With Septic Shock

The first objective of this study was to characterize the pharmacokinetics and pharmacodynamics of daptomycin with a daily dose of 12mg/kg in septic shock patient; the second objective is ...

Pharmacokinetic Study of Daptomycin in Healthy Chinese Subjects Living in China

The primary objective of this study is to characterise the pharmacokinetics and dose proportionality of daptomycin after single and multiple (once daily) 4mg/kg and 6 mg/kg doses of daptom...

Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis

multicenter, randomized, double blind study to describe the safety and efficacy of daptomycin (6 mg/kg q24h) with and without concomitant initial gentamicin combination therapy in the trea...

Medical and Biotech [MESH] Definitions

Strains of the genus Enterococcus that are resistant to the antibiotic VANCOMYCIN. The enterococci become resistant by acquiring plasmids carrying genes for VANCOMYCIN RESISTANCE.

The dose amount of poisonous or toxic substance or dose of ionizing radiation required to kill 50% of the tested population.

Mice selectively bred for hypersusceptibility to two-stage chemical skin carcinogenesis. They are also hypersusceptible to UV radiation tumorigenesis with single high-dose, but not chronic low-dose, exposures. SENCAR (SENsitive to CARcinogenesis) mice are used in research as an animal model for tumor production.

The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc.

A treatment schedule in which the total dose of radiation is divided into large doses.

Quick Search

DeepDyve research library

Relevant Topic

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...

Searches Linking to this Article